Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSpecifics awaits factory refurbishment:

This article was originally published in Clinica

Executive Summary

BioSpecifics, a Lynbrook, New York company producing collagenase for use in UK woundcare, orthopaedics and endoscopy company Smith & Nephew's Collagenase Santyl, has reported that normal production will be resumed when its newly refurbished facility gains FDA approval. The company, which is also engaged in a clinical trial for an injectable treatment for Peyronie's and Dupuytren's diseases, reported $2.8 million in revenues in the first quarter, compared with $1.4 million in the same period last year. It made a profit of $175,000 compared with a loss of $600,000.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel